OneBio Venture Studio, has secured a R20 million grant facility designed to accelerate the growth of high-impact biotechnology startups across the continent.
Deploying this capital marks a strategic intervention in the African venture landscape, where early-stage biotechnology often faces a structural funding vacuum. By providing non-dilutive capital, OneBio intends to bridge the high-risk “valley of death” that separates academic intellectual property from institutional investment readiness.
Objectives
The facility will be utilised to dismantle the barriers between laboratory research and global markets through three key pillars:
- Venture-Building Acceleration: Directly funding the operational and technical requirements of OneBio’s venture-building programs to reduce time-to-market.
- De-risking Early-Stage Innovation: Providing the necessary capital to achieve technical proof-of-concept.
- Bridging the Commercialisation Gap: Aligning high-impact research outputs with commercial market demands to ensure local scientific breakthroughs achieve global scale.
OneBio Venture Studio remains committed to building a local biotech ecosystem that leverages local talent to solve global challenges. This grant facility reinforces OneBio’s role as a catalyst for biotech entrepreneurship in Africa, ensuring that the continent’s scientific intellectual property is fully realised.